Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence (VESTIGE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03443856
Recruitment Status : Recruiting
First Posted : February 23, 2018
Last Update Posted : July 24, 2019
Sponsor:
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC

Brief Summary:

The primary objective of the trial is to investigate if nivolumab plus ipilimumab given as adjuvant treatment improve disease free survival (DFS) in patients with stage Ib-IVa gastric and esophagogastric junction adenocarcinoma and high risk of recurrence (defined by ypN1-3 and/or R1 status) following neoadjuvant chemotherapy and resection.

Other study objectives:

  • To investigate the safety and effect of adjuvant immunotherapy on long term oncologic outcomes and quality of life of patients in the study
  • To correlate nutritional status assessment on outcomes and quality of life of patients

Condition or disease Intervention/treatment Phase
Gastric and Esophagogastric Junction Adenocarcinoma Drug: Nivolumab and Ipilimumab Other: chemotherapy Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 240 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Adjuvant Immunotherapy in Patients With Resected Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): an Open Label Randomized Controlled Phase-2-study
Actual Study Start Date : July 17, 2019
Estimated Primary Completion Date : April 2023
Estimated Study Completion Date : June 2026

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
chemotherapy arm
Completion of the perioperative treatment according to the 2016 ESMO guidelines (change of regimen is not allowed).
Other: chemotherapy
Completion of the perioperative treatment according to the 2016 ESMO guidelines (change of regimen is not allowed).

Experimental: immunotherapy arm
Treatment: Nivolumab 1 mg/kg IV Q3W plus Ipilimumab 3 mg/kg IV Q3W for 4 cycles (3 months) followed by nivolumab 240 mg flat-dose IV Q2W for 9 months.Total treatment time 1 year. No chemotherapy.
Drug: Nivolumab and Ipilimumab
Nivolumab 1 mg/kg IV Q3W plus Ipilimumab 3 mg/kg IV Q3W for 4 cycles (3 months) followed by nivolumab 240 mg flat-dose IV Q2W for 9 months.Total treatment time 1 year




Primary Outcome Measures :
  1. Disease free survival (DFS) [ Time Frame: 22 months after last patient in ]
    Disease free survival is defined as the time interval between randomization and the date of disease recurrence or death from any cause, whichever comes first. Patients alive with no disease recurrence are censored at the date of the last follow-up examination. randomization and the date of disease recurrence or death from any cause, whichever comes first.


Secondary Outcome Measures :
  1. Overall survival (OS) [ Time Frame: 5 years after last patient in ]
    Overall survival is defined as the time interval between the date of randomization and the date of death from any cause. Patients who are still alive when last traced are censored at the date of last follow up.

  2. Loco-regional failure rates [ Time Frame: 5 years after last patient in ]
    Local recurrence is defined as evidence of tumor in the anastomotic area. Regional recurrence is defined as evidence of tumor in the locoregional lymph nodes or other surrounding structures apart from the anastomotic site. Death in absence of loco-regional failure will be considered as a competing risk in the estimation of the cumulative incidence of loco-regional failures. Patients who have not had any such event at the time of data analysis will be censored at the date of the last follow-up examination.

  3. Distant failure rates [ Time Frame: 5 years after last patient in ]

    The diagnosis of distant recurrence requires imaging confirmed by pathology. Once recurrence is confirmed, the date of recurrence is the first date when recurrence was suspected.

    Distant recurrence is defined as recurrence not considered as local or regional.Death in absence of distant failure will be considered as a competing risk in the estimation of the cumulative incidence of distant failures. Patients who have not had any such event at the time of data analysis will be censored at the date of the last follow-up examination


  4. Rate of adverse events according to NCI-CTCAE [ Time Frame: 5 years after last patient in ]

    All adverse events will be recorded; the investigator will assess whether those events are drug related (reasonable possibility, no reasonable possibility) and this assessment will be recorded in the database for all adverse events. AEs will be collected at baseline from randomization.

    Only the worst grade per CTCAE category will be recorded per cycle. All adverse events must be followed until resolution or stabilization. Adverse Events of Special Interest for ipilimumab and nivolumab requiring a close follow-up were identified as a result of signals observed from previous studies involving the protocol treatments. These events require a close follow-up


  5. Quality of life assessed with the EORTC Quality of Life Questionnaire (QLQ-C30) version 3 [ Time Frame: questionnaires will be completed at baseline, week 6, 3 months, 6 months, 9 months, 12 months, 15 months ]
    Quality of life will be assessed with the EORTC Quality of Life Questionnaire (QLQ-C30) version 3. These include five functional scales (physical, role, emotional, social, and cognitive), three symptom (fatigue, nausea and vomiting and pain) and a global health status/QoL scale and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties). The primary HRQoL endpoints that are considered relevant for this study are global health status/QoL and physical functioning.A difference of 10 points on the 100-point QLQ-C30 scale between the two arms will be considered as clinically relevant



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically proven gastric, lower esophageal or GE-junction adenocarcinoma (Siewert I-III)
  • Subjects must have completed pre-operative chemotherapy with a fluoropyrimidine-platinum containing regimen and macroscopically complete surgery prior to randomization
  • Minimal duration of neoadjuvant chemotherapy should be 6 weeks, maximum 12 weeks.
  • Total or distal gastrectomy with D2 lymphadenectomy according to ESMO guidelines should have been completed for gastric and junctional Siewert type III cancers. Ivor Lewis or McKeown oesophagectomy with two field lymphadenectomy should have been performed for junctional Siewert type I cancers. For Siewert type II cancers either total gastrectomy with D2-lymphadenectomy or oesophagectomy with two field lymphadenectomy should have been completed. Open, minimal invasive or hybrid surgical approaches are acceptable as long as the requirements above are fulfilled.
  • Regardless of the type of surgery a minimum of 15 lymph nodes should have been resected and examined.
  • Recovered from surgery and fit for study treatment as assessed by a multidisciplinary team. Ideally, surgery should have been completed 1 month before at the maximum.
  • ypN1-3 status according to current (8th) version of TNM classification system. In case of an ypN0 status patients must meet the inclusion criterion of R1 resection.
  • R0 or R1 resection according to current (8th) version of TNM classification system. In case of R0 resection, patients must meet the inclusion criterion of ypN1-3
  • Availability of operative and pathology reports for review
  • WHO performance status score of 0 or 1
  • Age ≥ 18 years
  • Adequate organ function assessed within 7 days before randomization:
  • White blood cell count (WBC) > 2 x 109/L
  • Absolute neutrophil count (ANC) > 1.5 x 109/L
  • Platelets ≥ 100 x 109/L
  • Hemoglobin ≥ 9 g/dL
  • Measured/calculated creatinine clearance ≥ 60 mL/min (according to Cockroft-Gault formula).
  • Total bilirubin within normal limits (if the patient has documented Gilbert's disease ≤ 1.5 * ULN or direct bilirubin ≤ ULN)
  • Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 1.5ULN
  • All toxicities (exception alopecia) attributed to prior anti-cancer therapy must have resolved to grade 1 (NCI CTCAE version 4) or baseline before administration of study drug.
  • Availability of tumor tissue from the resected site of disease must be provided for biobanking
  • Women of childbearing potential (WOCBP*) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin (HCG)) within 24 hours prior to randomization
  • Patients of childbearing / reproductive potential should use highly effective method of birth control measures during the study treatment period and for at least 5 months after the last study treatment. A highly effective method of birth control is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly.
  • Female subjects who are breast feeding should discontinue nursing prior to the first dose of study treatment and until 5 months after the last study treatment.
  • Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
  • Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations.

Exclusion Criteria:

  • R2 resection status
  • M1 stage according to current (8th) version of TNM classification system
  • Patients who have undergone complete resection of metastases
  • Impaired renal, hepatic, cardiac, pulmonary or endocrine status that compromises the eligibility of the patient for postoperative chemotherapy or immunotherapy
  • Subjects with previous malignancies are excluded unless a complete remission or complete resection was achieved at least 5 years prior to study entry. Adequately treated cervical carcinoma in situ, and localized non-melanoma skin cancer are no exclusion criteria, regardless of timepoint of diagnosis.
  • Subjects with active, known, or suspected infectious or autoimmune disease
  • Patients who have received antibiotics within the last 14 days before randomization are excluded.
  • Subjects with Type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to enroll
  • Subjects with a condition requiring systemic treatment with either corticosteroids (≥ 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of study drug administration
  • Subjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity
  • Subjects with > Grade 1 peripheral neuropathy
  • Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
  • Prior or concomitant treatment with radiotherapy/radiochemotherapy
  • Any positive test result for HBV or HCV indicating acute or chronic infection
  • Known history of testing positive for HIV or known AIDS
  • Known uncontrollable hypersensitivity to the components of cisplatin/oxaliplatin, fluorouracil (5-FU) or capecitabine, epirubicine or docetaxel
  • Known dihydropyrimidine dehydrogenase (DPD) deficiency
  • Ongoing or concomitant use of the antiviral drug sorivudine or its chemically related analogs, such as brivudine.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03443856


Contacts
Layout table for location contacts
Contact: EORTC HQ +32 2 774 16 11 1707@eortc.org

Locations
Layout table for location information
Czechia
Masaryk Memorial Cancer Institute Not yet recruiting
Brno, Czechia
Principal Investigator: Radka Obermannova         
France
Hôpital Privé Jean Mermoz Not yet recruiting
Lyon, France
Principal Investigator: Pascal Artru         
Gustave Roussy Not yet recruiting
Villejuif, France
Principal Investigator: Valérie Boige, Dr.         
Germany
SLK-Kliniken Heilbronn Recruiting
Heilbronn, Germany
Principal Investigator: Uwe Martens         
Universitaetsklinikum Leipzig-Ambulanzen/Sprechstunden Recruiting
Leipzig, Germany
Contact: Florian Lordick         
Israel
Rambam Health Care Campus, Oncology Institute Not yet recruiting
Haifa, Israel
Principal Investigator: Irit Ben-Aharon         
Rabbin Medical Centre - Tel Aviv Not yet recruiting
Tel Aviv, Israel
Principal Investigator: Baruch Brenner         
Italy
Azienda Ospedaliera a Papa Giovanni XXIII Not yet recruiting
Bergamo, Italy
Principal Investigator: Mario Mandala         
Istituto Europeo di Oncologia Not yet recruiting
Milan, Italy
Principal Investigator: Alessandra Cella         
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" Not yet recruiting
Napoli, Italy
Principal Investigator: Antonio Avallone         
Norway
Oslo University Hospital - Ullevaal Hospital Not yet recruiting
Oslo, Norway
Principal Investigator: Ghazwan Al-Haidari         
Poland
Maria Sklodowska-Curie Memorial Cancer Centre Not yet recruiting
Warsaw, Poland, 02 781
Principal Investigator: Lucjan Wyrwicz, Dr.         
Portugal
Champalimaud Cancer Centre Not yet recruiting
Lisboa, Portugal
Principal Investigator: Nuno Couto         
Instituto Portuguès de Oncologia do Porto Not yet recruiting
Porto, Portugal
Principal Investigator: Nuno Sousa         
Spain
Institut Catalan d'Oncologia - ICO Badalona Not yet recruiting
Badalona, Spain
Principal Investigator: Cristina Buges         
Hospital Universitario 12 de Octubre Not yet recruiting
Madrid, Spain
Principal Investigator: Carlos Gomez         
Complejo Hospitalario A Not yet recruiting
Pamplona, Spain
Principal Investigator: Antonio Viudez         
Hospital Clinico Universitario de Valencia Not yet recruiting
Valencia, Spain
Principal Investigator: Andres Cervantes         
United Kingdom
University Hospitals Birmingham NHS Foundation Trust Not yet recruiting
Birmingham, United Kingdom
Principal Investigator: Victoria Kunene         
Cambridge University Hospital NHS Not yet recruiting
Cambridge, United Kingdom
Principal Investigator: Elizabeth Smyth         
Royal Marsden Hospital Not yet recruiting
London, United Kingdom
Principal Investigator: Ian Chau         
University College London Hospitals NHS Foundation Trust Not yet recruiting
London, United Kingdom
Principal Investigator: Kai-Keen Shiu         
Royal Marsden Hospital Not yet recruiting
Sutton, United Kingdom
Principal Investigator: Ian Chau         
Sponsors and Collaborators
European Organisation for Research and Treatment of Cancer - EORTC
Investigators
Layout table for investigator information
Study Chair: Florian Lordick Universitaetsklinikum Leipzig-Ambulanzen/Sprechstunden, Leipzig, Germany
Study Chair: Maren Knoedler Universitaetsklinikum Leipzig-Ambulanzen/Sprechstunden, Leipzig, Germany
Study Chair: Elizabeth Smyth Cambridge University Hospital NHS - Cambridge, UK

Layout table for additonal information
Responsible Party: European Organisation for Research and Treatment of Cancer - EORTC
ClinicalTrials.gov Identifier: NCT03443856     History of Changes
Other Study ID Numbers: EORTC 1707-GITCG
2018-000406-36 ( EudraCT Number )
First Posted: February 23, 2018    Key Record Dates
Last Update Posted: July 24, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Additional relevant MeSH terms:
Layout table for MeSH terms
Adenocarcinoma
Stomach Neoplasms
Recurrence
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Disease Attributes
Pathologic Processes
Nivolumab
Ipilimumab
Antineoplastic Agents, Immunological
Antineoplastic Agents